SC suggests meeting of stakeholders to discuss quality, shortage of antiretroviral drugs for HIV patients

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-07-12 08:40 GMT | Update On 2024-07-16 15:01 GMT

New Delhi: The Supreme Court has made a suggestion of conducting a meeting between the Centre, National AIDS Control Organisation (NACO), and an organisation dedicated to AIDS patients to address concerns regarding the quality and shortage of antiretroviral drugs used in the treatment of HIV.

The bench overseeing the case, composed of Chief Justice D Y Chandrachud and Justices JB Pardiwala and Manoj Misra, was hearing a Public Interest Litigation (PIL) filed in 2022 by the NGO 'Network of People Living with HIV/AIDS'. The PIL alleged a shortage of antiretroviral drugs for HIV patient treatment.

Referring to the shortage of antiretroviral drugs in the country during the COVID-19 pandemic, the bench noted the submissions of Additional Solicitor General Aishwarya Bhati, appearing for the Centre, and senior advocate Anand Grover, representing the petitioner NGO, and said "dust has now settled" and there were enough medicines available.

"Quality of drugs is a major issue. We would like to discuss the issue with them (Centre and NACO)," Grover said and acknowledged that there was no shortage of medicines.

"We suggest that the meeting be held at senior level within two weeks. Thereafter, we will permit suggestions to be placed on record to ensure all concerns are taken care of," the CJI said.

Antiretroviral therapy (ART) involves treatment of people infected with human immunodeficiency virus (HIV) using anti-HIV drugs.

According to PTI, the plea has contended that non-availability of drugs at the AntiRetroViral Therapy Centres of the National AIDS Control Organisation hampers treatment of those living with HIV/AIDS.

Read also: WHO introduces online platform MeDevIS for medical devices information

Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

SC suggests meeting of stakeholders to discuss quality, shortage of antiretroviral drugs for HIV patients

Similar News

EMA Committee approves update to Novo Nordisk Rybelsus label to reflect cardiovascular benefits

Aurobindo Pharma arm incorporates new wholly owned subsidiary in Malaysia

Natco Pharma gets USFDA EIR for Kothur Pharma division

Roche to acquire 89bio for up to USD 3.5 billion

Lupin bags USFDA approval for Multiple myeloma treatment

Biocon Biologics wins USFDA nod for Bosaya and Aukelso, Denosumab Biosimilars

Cocrystals of Approved APIs to Be Treated as New Drugs, Clarifies CDSCO

India ranks among top global contributors in adverse event reporting: DCGI